Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer (vol 380, pg 1235, 2019)

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer (N Engl J Med 2019;380:1235-1246). In Table 1 (page 1239), the values provided for Presence of lymph nodes on central imaging review were incorrect. In the Darolutamide column, the values for Yes should have been 100 (10.5), rather than 163 (17), and the values for No should have been 855 (89.5), rather than 792 (83). In the Placebo column, the values for Yes should have been 66 (11.9), rather than 158 (29), and the values for No should have been 488 (88.1), rather than 396 (71). The article is correct at NEJM.org. . . .

Automated summary

This article points out incorrect data regarding the application of Darolutamide in nonmetastatic, castration-resistant prostate cancer.